Description

This issue of Vital Signs, released on December 6, 2010, provides a strategic overview of key issues and trends relating to next-generation sequencing. Additionally, a company spotlight is provided for GenturaDx, a company who has an exclusive license to more than 100 patents for assays, which should allow the company to develop an incredibly broad and robust menu of tests. Reimbursement and regulatory news from the FDA is also provided for the week of November 15, 2010.